{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/mck-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/mck-stock-analysis/data.json",
 "title": "McKesson (MCK) Stock Forecast & Price Target (2026)",
 "description": "Is McKesson Corporation (MCK) a Buy or Sell today? Get the latest AI trade setup, key support levels and risk analysis. Updated daily.",
 "headline": "McKesson Corporation (MCK)",
 "published": "2026-08-30T09:11:00+00:00",
 "modified": "2026-09-11T21:26:23.408+00:00",
 "generated": "2026-09-11T21:37:28.852Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "MCK",
  "name": "McKesson Corporation",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Distribution",
  "country": "United States",
  "website": "https://www.mckesson.com"
 },
 "quote": {
  "price": 881.51,
  "previousClose": 880.86,
  "change": 0.65,
  "changePercent": 0.07,
  "open": 888.37,
  "high": 893.91998,
  "low": 874.31,
  "volume": 838423,
  "averageVolume": 874092,
  "marketCap": 102775572054,
  "fiftyTwoWeekHigh": 999,
  "fiftyTwoWeekLow": 679.65002,
  "marketOpen": false,
  "asOf": "2026-09-11T21:26:22.000Z"
 },
 "statistics": {
  "pe": 23.634558,
  "eps": 37.27,
  "dividendYield": 0.004267635267118957,
  "beta": 0.307,
  "priceToSales": 0.24988815,
  "priceToBook": -80.38480672638386,
  "revenueTtm": 410983006208,
  "grossMargin": 0.03496868475991649,
  "returnOnEquity": -5.709832134292566
 },
 "technicals": {
  "rsi": 57.03,
  "macd": 10.64,
  "sma50": 857.41,
  "sma200": 843.8,
  "rsiSignal": "Neutral",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 74,
  "consensus": "Buy",
  "fairValue": 1000,
  "analystTarget": 1000,
  "analystCount": 18,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-11T21:26:22.000Z",
  "priceAtAnalysis": 881.51001,
  "volatility": {
   "daily": 2,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 863.88,
  "aggressiveEntry": 881.51,
  "stopLoss": 834.85,
  "stopLossPercent": 3.36,
  "targets": [
   907.07,
   950.27,
   993.46
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 677.31,
    "base": 985.44,
    "upside90th": 1433.75
   },
   {
    "year": 2028,
    "downside10th": 648.25,
    "base": 1101.63,
    "upside90th": 1872.1
   },
   {
    "year": 2029,
    "downside10th": 643.27,
    "base": 1231.52,
    "upside90th": 2357.71
   },
   {
    "year": 2030,
    "downside10th": 650.37,
    "base": 1376.72,
    "upside90th": 2914.26
   },
   {
    "year": 2031,
    "downside10th": 665.46,
    "base": 1539.04,
    "upside90th": 3559.37
   },
   {
    "year": 2032,
    "downside10th": 686.71,
    "base": 1720.49,
    "upside90th": 4310.54
   },
   {
    "year": 2033,
    "downside10th": 713.21,
    "base": 1923.35,
    "upside90th": 5186.75
   },
   {
    "year": 2034,
    "downside10th": 744.52,
    "base": 2150.11,
    "upside90th": 6209.36
   },
   {
    "year": 2035,
    "downside10th": 780.44,
    "base": 2403.62,
    "upside90th": 7402.71
   },
   {
    "year": 2036,
    "downside10th": 820.96,
    "base": 2687.02,
    "upside90th": 8794.69
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "MCK Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$888.37",
    "Day Range": "$874.31 to $893.92",
    "Prev Close": "$880.86",
    "Volume": "838.4K",
    "52-Week Range": "$679.65 to $999.00",
    "Market Cap": "$102.78B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a notable discount to sector peers (-26%), which may indicate undervaluation or specific company headwinds."
   ]
  },
  {
   "id": "analysis",
   "title": "MCK Analysis",
   "text": [
    "McKesson Corporation (MCK) is trading above its 50-day and 200-day moving averages ($857.41 and $843.80), indicating a generally positive long-term trend, though it is currently below its 20-day EMA. The RSI is at 57.03, signaling neutral momentum, and the MACD is positive at 10.64, suggesting some underlying bullish pressure. Volume has been slightly below average, down 4.1%. The stock is currently trading within a range defined by its moving averages, with the 20-day EMA at $885.75 acting as near-term resistance and the 50-day SMA at $857.41 serving as support. The neutral RSI suggests that the stock is neither overbought nor oversold, implying room for potential price appreciation or consolidation. Investors should monitor the price action around these key moving averages for directional cues.",
    "Insiders have sold a substantial $83.6 million worth of stock, indicating potential concerns or a need for liquidity among management.",
    "McKesson Corporation has a history of exceeding analyst EPS estimates, most recently by 4.09%, demonstrating operational resilience and effective execution.",
    "MCK's P/E ratio of 23.63 is below the healthcare sector median of 31.9, suggesting potential for multiple expansion as the market recognizes its value.",
    "Projected revenue growth of 7.00% for the current and next quarters, coupled with 7.7% year-over-year growth, supports continued business expansion.",
    "McKesson Corporation (MCK) is expected to maintain its positive trajectory over the next 6-12 months, supported by its strong earnings performance and a valuation that appears attractive relative to the healthcare sector. The median analyst price target of $1000 suggests a potential upside of 13.4% from the current price of $881.51, reflecting confidence in the company's operational efficiency and market position. Key factors that could alter this outlook include a reversal of the current insider selling trend, which could signal renewed management confidence, or a significant shift in regulatory policy impacting pharmaceutical distribution. Conversely, any acceleration in revenue growth beyond the projected 7.00% or a successful integration of new business segments could provide further upside catalysts. The company's ability to sustain its earnings beats will be critical in driving future stock performance."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider transaction activity closely; while a heavy sell signal is present, a shift towards net buying could be a strong bullish indicator.",
     "Pay attention to the $857.41 level (50-day SMA) as a key support zone; a break below this could signal a short-term trend reversal.",
     "Given the neutral RSI, consider waiting for a clearer signal of upward momentum before initiating new positions, or look for opportunities on pullbacks towards support levels."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Heavy Insider Selling Activity",
     "text": "Insiders have sold a substantial $83.6 million worth of stock, indicating potential concerns or a need for liquidity among management.",
     "source": "Insider Trading Data"
    },
    {
     "type": "Bullish",
     "title": "Consistent Earnings Beats",
     "text": "McKesson Corporation has a history of exceeding analyst EPS estimates, most recently by 4.09%, demonstrating operational resilience and effective execution.",
     "source": "Earnings Reports"
    },
    {
     "type": "Bullish",
     "title": "Valuation Discount to Sector Peers",
     "text": "MCK's P/E ratio of 23.63 is below the healthcare sector median of 31.9, suggesting potential for multiple expansion as the market recognizes its value.",
     "source": "Fundamental Analysis"
    },
    {
     "type": "Bullish",
     "title": "Positive Revenue Growth Outlook",
     "text": "Projected revenue growth of 7.00% for the current and next quarters, coupled with 7.7% year-over-year growth, supports continued business expansion.",
     "source": "Revenue Estimates"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "McKesson Corporation (MCK) presents a compelling valuation, trading at a P/E ratio of 23.63, which is below the healthcare sector median of 31.9. This suggests the stock may be undervalued relative to its peers, especially considering its revenue growth of 7.7%, which is slightly above the sector average of 8.1% (though the sector average is based on a median of 44 stocks). The company's earnings per share stands at $37.27. Profitability appears strong, with recent earnings reports consistently beating analyst estimates, indicating operational efficiency. The company's balance sheet strength is implied by its market capitalization of $102.8 billion and consistent revenue growth. The current valuation, coupled with positive earnings trends and sector-relative discount, supports a favorable fundamental outlook.",
    "McKesson Corporation (MCK) has a strong track record of exceeding analyst earnings expectations, most recently reporting an EPS of $9.93 against an estimate of $9.54, a 4.09% surprise, though the stock saw a slight decline of 0.67% post-announcement. Prior to this, the company delivered a 6.02% EPS surprise in the previous quarter. Over the last four reported quarters, MCK has consistently beaten estimates, demonstrating reliable operational performance.",
    "A significant risk for McKesson Corporation (MCK) stems from the heavy insider selling signal, with over $83.6 million in sales reported, indicating a lack of confidence from management in the short term. While the stock is trading above key moving averages, the neutral RSI suggests momentum could stall. Additionally, the healthcare sector, while generally stable, faces ongoing regulatory scrutiny and potential pricing pressures that could impact future profitability."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "102.78B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "23.63"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "37.27"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.3859%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "999.00"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "679.65"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Neutral SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($857.41) above the 200-day SMA ($843.80), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "57.03"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "10.64"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "857.41"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "843.80"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.01",
    "Correlation with Nasdaq 100 (QQQ)": "-0.09",
    "Correlation with Bitcoin (BTC)": "-0.09",
    "Correlation with Gold (XAU)": "-0.01"
   }
  },
  {
   "id": "trade-plans",
   "title": "MCK Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (57.0) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$907.07",
    "TARGET 2": "$950.27",
    "TARGET 3": "$993.46",
    "STOP LOSS": "$834.85"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "2.00%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in MCK in September 2016 would be worth about $48,809 today, compared with about $35,030 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in MCK today could grow to about $30,482 by 2036 in the base case, with a bull case near $99,768 and a bear case around $9,313. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "MCK Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $1,377 for MCK by 2030 in the base case, from $882 today (1.6x over 4 years). The downside path ends near $650. These are outcomes of a Monte Carlo simulation run on MCK's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using MCK's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "MCK simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$677",
        "$985",
        "$1,434"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$648",
        "$1,102",
        "$1,872"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$643",
        "$1,232",
        "$2,358"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$650",
        "$1,377",
        "$2,914"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$665",
        "$1,539",
        "$3,559"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$687",
        "$1,720",
        "$4,311"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$713",
        "$1,923",
        "$5,187"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$745",
        "$2,150",
        "$6,209"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$780",
        "$2,404",
        "$7,403"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$821",
        "$2,687",
        "$8,795"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "OFIX Orthofix Medical Inc. NASDAQ $8.91 +2.53%",
     "url": "https://clearank.com/stock/ofix-stock-analysis/"
    },
    {
     "text": "CRNX Crinetics Pharmaceuticals, Inc. NASDAQ $84.95 +0.00%",
     "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
    },
    {
     "text": "DHR Danaher Corp. NYSE $200.53 -2.11%",
     "url": "https://clearank.com/stock/dhr-stock-analysis/"
    },
    {
     "text": "GEHC GE HealthCare Technologies Inc. NASDAQ $64.81 -0.5601%",
     "url": "https://clearank.com/stock/ge-healthcare-gehc/"
    },
    {
     "text": "LEGN Legend Biotech Corporation NASDAQ $19.91 -2.83%",
     "url": "https://clearank.com/stock/legend-biotech-legn/"
    },
    {
     "text": "RMD ResMed Inc. NYSE $216.92 -1.21%",
     "url": "https://clearank.com/stock/rmd-stock-analysis/"
    },
    {
     "text": "MRNA Moderna Inc. NASDAQ $148.15 +8.44%",
     "url": "https://clearank.com/stock/moderna-mrna/"
    },
    {
     "text": "ELV Elevance Health, Inc. NYSE $416.94 +0.0960%",
     "url": "https://clearank.com/stock/elv-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "RKLB vs ASTS Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/rklb-vs-asts/"
    },
    {
     "text": "LLY vs ABBV Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/lly-vs-abbv/"
    },
    {
     "text": "Invesco QQQ vs Vanguard S&P 500 (VOO) Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/qqq-vs-voo/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "MCK Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$83.6M",
    "Insiders": "11",
    "Avg Transaction": "$2.6M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in MCK",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Sep 27, 2017",
       "cells": [
        "HAMMERGREN JOHN H Chief Executive Officer",
        "Sell",
        "300.0K",
        "$46.4M"
       ]
      },
      {
       "label": "Sep 22, 2017",
       "cells": [
        "HAMMERGREN JOHN H Chief Executive Officer",
        "Sell",
        "225.0K",
        "$34.1M"
       ]
      },
      {
       "label": "Sep 29, 2017",
       "cells": [
        "HAMMERGREN JOHN H Chief Executive Officer",
        "Sell",
        "199.0K",
        "$30.6M"
       ]
      },
      {
       "label": "Jul 11, 2025",
       "cells": [
        "TYLER BRIAN SCOTT Chief Executive Officer",
        "Sell",
        "19.4K",
        "$13.7M"
       ]
      },
      {
       "label": "Jun 6, 2025",
       "cells": [
        "TYLER BRIAN SCOTT Chief Executive Officer",
        "Sell",
        "19.4K",
        "$13.7M"
       ]
      },
      {
       "label": "Oct 9, 2023",
       "cells": [
        "TYLER BRIAN SCOTT Chief Executive Officer",
        "Sell",
        "28.7K",
        "$12.8M"
       ]
      },
      {
       "label": "Nov 3, 2021",
       "cells": [
        "SCHECHTER LORI A General Counsel",
        "Sell",
        "54.4K",
        "$11.9M"
       ]
      },
      {
       "label": "Nov 7, 2023",
       "cells": [
        "TYLER BRIAN SCOTT Chief Executive Officer",
        "Sell",
        "24.0K",
        "$11.0M"
       ]
      },
      {
       "label": "Sep 8, 2023",
       "cells": [
        "TYLER BRIAN SCOTT Chief Executive Officer",
        "Sell",
        "25.2K",
        "$10.7M"
       ]
      },
      {
       "label": "Dec 14, 2017",
       "cells": [
        "HAMMERGREN JOHN H Chief Executive Officer",
        "Sell",
        "65.0K",
        "$10.4M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=McKesson+Corporation&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is McKesson Corporation (MCK) stock a buy right now?",
   "answer": "McKesson Corporation (MCK) is currently rated a Buy by Wall Street analysts, with a median price target of $1000, suggesting a 13.4% upside from its current price of $881.51. The company has a history of beating earnings estimates and trades at a discount to its sector's median P/E ratio."
  },
  {
   "question": "What is McKesson Corporation's (MCK) projected revenue growth?",
   "answer": "McKesson Corporation (MCK) is projected to achieve revenue growth of 7.00% for the current quarter and 7.00% for the next quarter. For the current year, revenue growth is estimated at 7.00%, reaching approximately $431.9 billion."
  },
  {
   "question": "What are the main risks facing McKesson Corporation (MCK)?",
   "answer": "The primary risks for McKesson Corporation (MCK) include significant insider selling totaling $83.6 million, a neutral RSI suggesting potential momentum loss, and the general regulatory and pricing pressures inherent in the healthcare sector."
  },
  {
   "question": "How does McKesson Corporation (MCK) compare to its sector averages?",
   "answer": "McKesson Corporation (MCK) trades at a P/E ratio of 23.63, below the healthcare sector median of 31.9, and its revenue growth of 7.7% is slightly above the sector median of 8.1%. Its ROE is 6.9%, compared to the sector median of 6.9%."
  },
  {
   "question": "What is the outlook for McKesson Corporation (MCK) stock?",
   "answer": "The outlook for McKesson Corporation (MCK) is cautiously optimistic, with Wall Street analysts maintaining a Buy rating and a median price target of $1000. The company's consistent earnings performance and favorable valuation relative to its peers support this view, though insider selling warrants monitoring."
  },
  {
   "question": "What is McKesson Corporation's (MCK) dividend yield?",
   "answer": "McKesson Corporation (MCK) pays a dividend with a current yield of approximately 0.39%."
  },
  {
   "question": "What is McKesson Corporation's (MCK) stock price prediction for 2030?",
   "answer": "Based on Monte Carlo simulations, McKesson Corporation's (MCK) stock price is projected to be $1376.72 in 2030 under a base case scenario, with a downside projection of $650.37 and an upside projection of $2914.26. These are statistical outcomes, not guarantees."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "OFIX",
    "name": "Orthofix Medical Inc. NASDAQ",
    "price": "$8.91",
    "change": "+2.53%",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "CRNX",
    "name": "Crinetics Pharmaceuticals, Inc. NASDAQ",
    "price": "$84.95",
    "change": "+0.00%",
    "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
   },
   {
    "ticker": "DHR",
    "name": "Danaher Corp. NYSE",
    "price": "$200.53",
    "change": "-2.11%",
    "url": "https://clearank.com/stock/dhr-stock-analysis/"
   },
   {
    "ticker": "GEHC",
    "name": "GE HealthCare Technologies Inc. NASDAQ",
    "price": "$64.81",
    "change": "-0.5601%",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "LEGN",
    "name": "Legend Biotech Corporation NASDAQ",
    "price": "$19.91",
    "change": "-2.83%",
    "url": "https://clearank.com/stock/legend-biotech-legn/"
   },
   {
    "ticker": "RMD",
    "name": "ResMed Inc. NYSE",
    "price": "$216.92",
    "change": "-1.21%",
    "url": "https://clearank.com/stock/rmd-stock-analysis/"
   },
   {
    "ticker": "MRNA",
    "name": "Moderna Inc. NASDAQ",
    "price": "$148.15",
    "change": "+8.44%",
    "url": "https://clearank.com/stock/moderna-mrna/"
   },
   {
    "ticker": "ELV",
    "name": "Elevance Health, Inc. NYSE",
    "price": "$416.94",
    "change": "+0.0960%",
    "url": "https://clearank.com/stock/elv-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "RKLB vs ASTS Comparison",
    "name": "",
    "url": "https://clearank.com/compare/rklb-vs-asts/"
   },
   {
    "ticker": "LLY vs ABBV Comparison",
    "name": "",
    "url": "https://clearank.com/compare/lly-vs-abbv/"
   },
   {
    "ticker": "Invesco QQQ vs Vanguard S&P 500 (VOO) Comparison",
    "name": "",
    "url": "https://clearank.com/compare/qqq-vs-voo/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "EXC",
    "text": "Exelon Corp.",
    "url": "https://clearank.com/stock/exc-stock-analysis/"
   },
   {
    "ticker": "GWW",
    "text": "W.W. Grainger Inc.",
    "url": "https://clearank.com/stock/gww-stock-analysis/"
   },
   {
    "ticker": "CDE",
    "text": "Coeur Mining Inc.",
    "url": "https://clearank.com/stock/cde-stock-analysis/"
   },
   {
    "ticker": "CCI",
    "text": "Crown Castle Inc.",
    "url": "https://clearank.com/stock/cci-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "NEAR/USD",
    "text": "↑ 18.46%",
    "url": "https://clearank.com/crypto/near-protocol-near-usd/"
   },
   {
    "ticker": "THETA/USD",
    "text": "↑ 15.25%",
    "url": "https://clearank.com/crypto/theta-network-theta-usd/"
   },
   {
    "ticker": "XHLD",
    "text": "↑ 15.04%",
    "url": "https://clearank.com/stock/xhld-stock-analysis/"
   },
   {
    "ticker": "HPE",
    "text": "↑ 10.41%",
    "url": "https://clearank.com/stock/hewlett-packard-enterprise-hpe/"
   },
   {
    "ticker": "DELL",
    "text": "↑ 10.23%",
    "url": "https://clearank.com/stock/dell-technologies-dell/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "LEGN",
    "text": "Legend Biotech",
    "url": "https://clearank.com/stock/legend-biotech-legn/"
   },
   {
    "ticker": "LLY",
    "text": "Eli Lilly",
    "url": "https://clearank.com/stock/eli-lilly-lly/"
   },
   {
    "ticker": "MDT",
    "text": "Medtronic plc",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   },
   {
    "ticker": "MOH",
    "text": "Molina Healthcare Inc.",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "MRK",
    "text": "Merck",
    "url": "https://clearank.com/stock/merck-mrk/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/08/mck-mckesson-analysis-2026-08.png",
     "url": "https://clearank.com/wp-content/uploads/2026/08/mck-mckesson-analysis-2026-08.png",
     "width": "1280",
     "height": "720",
     "caption": "McKesson Corporation (MCK) stock price analysis chart for August 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/mck-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/mck-stock-analysis/",
        "name": "McKesson Corporation (MCK) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/mck-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/mck-stock-analysis/",
     "name": "McKesson (MCK) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-08-30T09:11:00+00:00",
     "dateModified": "2026-09-11T21:26:23+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/08/mck-mckesson-analysis-2026-08.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/mck-stock-analysis/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "McKesson (MCK) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-08-30T09:11:00+00:00",
     "dateModified": "2026-09-11T21:26:23+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Is McKesson Corporation (MCK) a Buy or Sell today? Get the latest AI trade setup, key support levels and risk analysis. Updated daily.",
     "name": "McKesson (MCK) Stock Forecast & Price Target (2026)",
     "@id": "https://clearank.com/stock/mck-stock-analysis/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/mck-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/08/mck-mckesson-analysis-2026-08.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/mck-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "McKesson Corporation (MCK)",
   "tickerSymbol": "MCK",
   "url": "https://clearank.com/stock/mck-stock-analysis/",
   "description": "AI-powered financial analysis for McKesson Corporation (MCK) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NYSE",
   "offers": {
    "@type": "Offer",
    "price": 881.51001,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/mck-stock-analysis/",
    "priceValidUntil": "2026-09-12"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is McKesson Corporation (MCK) stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "McKesson Corporation (MCK) is currently rated a Buy by Wall Street analysts, with a median price target of $1000, suggesting a 13.4% upside from its current price of $881.51. The company has a history of beating earnings estimates and trades at a discount to its sector's median P/E ratio."
     }
    },
    {
     "@type": "Question",
     "name": "What is McKesson Corporation's (MCK) projected revenue growth?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "McKesson Corporation (MCK) is projected to achieve revenue growth of 7.00% for the current quarter and 7.00% for the next quarter. For the current year, revenue growth is estimated at 7.00%, reaching approximately $431.9 billion."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main risks facing McKesson Corporation (MCK)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks for McKesson Corporation (MCK) include significant insider selling totaling $83.6 million, a neutral RSI suggesting potential momentum loss, and the general regulatory and pricing pressures inherent in the healthcare sector."
     }
    },
    {
     "@type": "Question",
     "name": "How does McKesson Corporation (MCK) compare to its sector averages?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "McKesson Corporation (MCK) trades at a P/E ratio of 23.63, below the healthcare sector median of 31.9, and its revenue growth of 7.7% is slightly above the sector median of 8.1%. Its ROE is 6.9%, compared to the sector median of 6.9%."
     }
    },
    {
     "@type": "Question",
     "name": "What is the outlook for McKesson Corporation (MCK) stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The outlook for McKesson Corporation (MCK) is cautiously optimistic, with Wall Street analysts maintaining a Buy rating and a median price target of $1000. The company's consistent earnings performance and favorable valuation relative to its peers support this view, though insider selling warrants monitoring."
     }
    },
    {
     "@type": "Question",
     "name": "What is McKesson Corporation's (MCK) dividend yield?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "McKesson Corporation (MCK) pays a dividend with a current yield of approximately 0.39%."
     }
    },
    {
     "@type": "Question",
     "name": "What is McKesson Corporation's (MCK) stock price prediction for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, McKesson Corporation's (MCK) stock price is projected to be $1376.72 in 2030 under a base case scenario, with a downside projection of $650.37 and an upside projection of $2914.26. These are statistical outcomes, not guarantees."
     }
    }
   ]
  }
 ]
}